Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase II Study to Explore the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL)

NCT00287105 is registered in ClinicalTrials.gov with Rennes University Hospital as lead sponsor.

NCT NCT00287105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00287105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase II Study to Explore the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL)
Lead sponsor
Rennes University Hospital
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2005
Completion date
March 3, 2017
Enrollment
49 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, philadelphia chromosome